Resumen

GONZALEZ-VELEZ, Abel et al. Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC). Gac. mex. oncol. [online]. 2021, vol.20, n.3, pp.111-123.  Epub 13-Dic-2021. ISSN 2565-005X.  https://doi.org/10.24875/j.gamo.21000005.

Lung cancer is the leading cause of death due to cancer worldwide; representing 18.4% of cancer mortality. Taking into account the impact of this pathology and the increase in the tendency of using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of non-small cell lung cancer (NSCLC), a brief review was conducted of the evidence that evaluates the efficacy and safety of these drugs. Finding that there is a benefit in using immune checkpoint inhibitors PD-1/PD-L1 for the treatment of patients with metastatic NSCLC evaluated by overall survival, progression-free survival and adverse effects when used as monotherapy compared to chemotherapy. Although in combination therapy the adverse effects are increased when compared to chemotherapy without immunotherapy. In addition, some predictive factors of hyperprogressive disease have been found, which can be used to identify patients who will not benefit from immune therapy, although there is room for further investigation.

Palabras llave : Non-small-cell lung carcinoma; Lung neoplasms; Programmed death-ligand 1 (PD-L1); Immunotherapy; Hyperprogressive disease.